We only have this paper's title and publication details.
Read it at the sourceEvaluates efficacy and tolerability of deucravacitinib in refractory psoriasis, suggesting promising outcomes.
No takes yet. Share an insight, caveat, or question.
Zohura et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: